Moreover, there have been several tantalizing clues that PPARβ/δ may also modulate aspects of lipid homeostasis [39] and it can be proposed as a possible pharmacological target for the treatment of obesity, IR, and dyslipidemia in order to contribute the potent vascular antiatherogenic effects [40]. The gene discussed is PPARD; the disease is obesity due to melanocortin 4 receptor deficiency.